Tumor Biology

, Volume 37, Issue 2, pp 1825–1834 | Cite as

Synergistic efficacy of γ-radiation together with gallium trichloride and/or doxorubicin against Ehrlich carcinoma in female mice

Original Article


Combining chemotherapy with radiotherapy represents a key oncology strategy for a more comprehensive attack toward cancers and improves treatment outcome for various solid tumor malignancies. The present study aims to evaluate the synergistic antitumor effect of γ-radiation together with gallium trichloride (GaCl3) and/or doxorubicin (DOX) against solid Ehrlich carcinoma (EC) in female mice. GaCl3 (300 mg/kg body weight (b.w.)) was administered by gavages daily on the seventh day after tumor inoculation, while the cytotoxic drug DOX (4 mg/kg b.w.) was administered intraperitoneally once a week. Whole-body γ-radiation was carried out at a dose 2 Gy once a week. Biochemical analysis showed that solid EC induced a significant increase in malondialdehyde (MDA) content with a significant decrease in the antioxidant state (glutathione peroxidase (GPx) and catalase (CAT) activities) and depleted serum iron concentration compared to normal control. Moreover, a significant increase was observed in calcium level and caspase-3 concentrations in both serum and tumor homogenate respectively associated with a significant alteration in heart, liver, and kidney functions, as compared to control. Treatment of EC-bearing mice with GaCl3and/or DOX combined with γ-radiation exposure significantly reduced tumor volume and displayed a significant improvement in most studied markers which may indicate a synergistic effect of this combination against organ dysfunction and cellular injury. The histopathologically investigation showed that treatment of animals bearing EC with GaCl3and/or DOX with γ-radiation exposure showed shrinkage in tumor lesions and wide zones of apoptotic cells with signs of regenerations. It was concluded that the combination of GaCl3and/or DOX with γ-radiation exposure resulted in super-additive cytotoxic effects on treatment of cancer cells.

Key words

Ehrlich solid tumor Doxorubicin Gallium trichloride γ-Radiation exposure Cardiomyopathy Hepatic and renal dysfunction 


  1. 1.
    Ozaslan M, Karagoz ID, Kilic IH, Guldur ME. Ehrlich ascites carcinoma. Afr J Biotechnol. 2011;10(13):2375–8.Google Scholar
  2. 2.
    Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem. 2004;279:25535–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanafi N, Mansour SZ. Antitumor Efficacy of salenostemma argel and/or y-irradiation against Ehrlich carcinoma. J Biol Sci. 2010;10(6):468–79.CrossRefGoogle Scholar
  4. 4.
    Raviraj J, Bokkasam VK, Kumar VS, Reddy US, Suman V. Radiosensitizers, radioprotectors, and radiation mitigators. Indian J Dent Res. 2014;25:83–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Hematol. 2002;42:283–96.CrossRefPubMedGoogle Scholar
  6. 6.
    Chitambar CR, Purpi DP. Novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma. Cells Leuk Res. 2010;34(7):950–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Chitambar CR. Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology. 2004;18:39–44.PubMedGoogle Scholar
  8. 8.
    Chitambar CR, Antholine WE. Iron-targeting antitumor activity of gallium compounds and novel insights into triapine-metal complexes. Antioxid Redox Signal. 2013;18(8):956–72.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Akhila JS, Deepa S, Alwar MC. Acute toxicity studies and determination of median lethal dose. Curr Sci. 2007;93:917–20.Google Scholar
  10. 10.
    Narang AS, Desai DS: Anticancer drug development unique aspects of pharmaceutical development. Y. Lu, R.I. Mahato (eds.), Pharmaceutical perspectives of cancer therapeutics 2009;49–92.Google Scholar
  11. 11.
    Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008;8:16–24.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 1967;69(4):696–705.PubMedGoogle Scholar
  13. 13.
    Buhl SN, Jackson KY. Optimal conditions and comparison of lactate dehydrogenase catalysis of the lactate-to-pyruvate and pyruvate-to-lactate reactions in human serum at 25, 30, and 37 degrees C. Clin Chem. 1978;24(5):828–31.PubMedGoogle Scholar
  14. 14.
    Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Path. 1957;28:56–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Dreux C. Analyse du serum humain. Ann Biol Clin. 1977;35:275–7.Google Scholar
  16. 16.
    Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chem Acta. 1971;31(1):87–96.CrossRefGoogle Scholar
  17. 17.
    Walter M, Gerade H. Determination of total bilirubin and its conjugated direct fraction. Microchem J. 1970;15:231–6.CrossRefGoogle Scholar
  18. 18.
    Gornal AC, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret. J Biol Chem. 1949;177:751.Google Scholar
  19. 19.
    Henry R J: Clinical chemistry: principle and techniques, 2nd Edition, Harper and Row. 1974;525.Google Scholar
  20. 20.
    Patton CJ, Crouch SR. Spectrophotometric and kinetics investigations of the Berthelot reaction for the determination of ammonia. Anal Chem. 1977;49:464–9.CrossRefGoogle Scholar
  21. 21.
    Tietz, NW: Fundamentals of clin. chem. (1976), 876Google Scholar
  22. 22.
    Barnett RN. A scheme for the comparison of quantitative methods. Am J Clin Pathol. 1965;43:562.CrossRefPubMedGoogle Scholar
  23. 23.
    Yoshioka TK, Kawada T, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Drury AR, Wallington EA: Carleton’s histological techniques 5th ed. Oxford University press. London.1980 pp.: 140.Google Scholar
  25. 25.
    Alyamkina EA, Nikolin VP, Popova NA, Dolgova EV, Proskurina AS, Orishchenko KE, et al. A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. Gen Vaccine Ther. 2010;8:1–10.CrossRefGoogle Scholar
  26. 26.
    Chen AY, Chen PMT, Chen YJ. DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis. 2012;4(4):390–7.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Jakupec MA, Keppler BK. Gallium in cancer treatment. Curr Top Med Chem. 2004;4(15):1575–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Laginha KM, Verwoert S, Gregory JR, Charrois, et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast tumors. Clin Cancer Res. 2005;11:6944–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2009;126:522–32.CrossRefGoogle Scholar
  30. 30.
    Hassan AI. The role of hyperthermia in potentiation of chemotherapy and radiotherapy in mice bearing solid tumor. Nat Sci. 2010;8(5):100–8.Google Scholar
  31. 31.
    Lee A, Levine M. Treatment of venous thromboembolism in cancer patients. Cancer Control. 2005;12:17–21.PubMedGoogle Scholar
  32. 32.
    Sallie R, Tredger JM, Williams R. Drugs and the liver. Part 1: testing liver function. Biopharm Drug Dispos. 1991;12(4):251–9.CrossRefPubMedGoogle Scholar
  33. 33.
    El-Demerdash FM. Antioxidant effect of vitamin E and selenium on lipid peroxidation, enzyme activities and biochemical parameters in rats exposed to aluminium. J Trace Elem Med Biol. 2004;18(1):113–21.CrossRefPubMedGoogle Scholar
  34. 34.
    He YT, Liu DW, Ding LY, Li Q, Xiao YH. Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis. World J Gastroenterol. 2004;10(5):703–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sridharamurthy NB, Yogananda R, Mahamood DR. Effect of leaf extracts of Rhynchosia beddomei on Ehrlich ascites carcinoma in mice. Int J Drug Dev Res. 2011;3(4):225–36.Google Scholar
  36. 36.
    Abdan M AL. Alfa-Lipoic acid controls tumor growth and modulates hepatic redox state in Ehrlich-ascites-carcinoma-bearing mice. Sci World J. 2012;6:1–6.CrossRefGoogle Scholar
  37. 37.
    Badr MOT, Edrees NMM, Abdallah AAM, El-Deen NAMN, Neamat-Allah ANF, Ismail HTH. Anti-tumour effects of Egyptian propolis on Ehrlich ascites carcinoma. Vet Ital. 2011;47:341–50.PubMedGoogle Scholar
  38. 38.
    Coles EH. Veterinary clinical pathology. 2nd ed. Philadelphia and London: W.B. Saunders Company; 1986. p. 193–246.Google Scholar
  39. 39.
    Said UZ, Ahmed NH, Medhat AM, Mustafa MM: Effects of omega-3 fatty acids against Ehrlich carcinoma-induced hepatic dysfunction. Journal of Cancer Research and Experimental Oncology 2014, 6(2): 20–28 2014Google Scholar
  40. 40.
    Eby GA. A hypothesis for anti-nanobacteria effects of gallium with observations from treating kidney disease. Med Hypothesis. 2008;71:584–90.CrossRefGoogle Scholar
  41. 41.
    Rajendran P, Nandakumar N, Rengarajan T, Palaniswami R, Gnanadhas EN, Lakshminarasaiah U, et al. Antioxidants and human diseases. J Clin Chim Acta. 2014;25(436C):332–47.CrossRefGoogle Scholar
  42. 42.
    Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35:32–46.CrossRefPubMedGoogle Scholar
  43. 43.
    Skrajnowska D, Bobrowska-Korczak B, Tokarz A, Bialek S, Jezierska E, Makowska J. Copper and resveratrol attenuates serum catalase, glutathione peroxidase, and element values in rats with DMBA-induced mammary carcinogenesis. Biol Trace Elem Res. 2013;156:271–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Sabina EP, Rasool M, Vedi M, Navaneethan D, Ravichander M, Parthasarthy P, Thella SR.: Hepatoprotective and antioxidant potential of withania somnifera against paracetamol-induced liver damage in rats. Int J Pharm. Pharm. 2013, Sci., 5(2): 648–651.Google Scholar
  45. 45.
    Bauer G. Targeting extracellular ROS signaling of tumour cells. J Anticancer Res. 2014;34(4):1467–82.Google Scholar
  46. 46.
    Huo W, Li ZM, Pan XY, Bao YM, An LJ. Antioxidant enzyme levels in pathogenesis of oral squamous cell carcinoma (OSCC). J Drug Res. 2014;64(11):629–32.CrossRefGoogle Scholar
  47. 47.
    Okuno T, Honda E, Arakawa T, Ogino H, Ueno H. Glutathione-dependent cell cycle G1 arrest and apoptosis induction in human lung cancer A549 cells caused by methylseleninic acid: comparison with sodium selenite. J Biol Pharm Bull. 2014;37(11):1831–7.CrossRefGoogle Scholar
  48. 48.
    Wang C, Yu J, Wang H, Zhang J, Wu N. (2014): Lipid peroxidation and altered anti-oxidant status in breast adenocarcinoma patients. J Drug Res. 2014;64(12):690–2.CrossRefGoogle Scholar
  49. 49.
    Singh R, Singh RK, Mahdi AA. Circadian periodicity of plasma lipid peroxides and other anti-oxidants as putative markers in gynecological malignancies. In Vivo. 2003;17:593–600.PubMedGoogle Scholar
  50. 50.
    Leperre A, Millart H, Prévost A, Kantelip JP, Lamiable D, Collery P. Gallium chloride effects on neonatal rat heart cells in culture, in standard and oxidative conditions. Fundam Clin Pharmacol. 1994;8:563–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Chitambar CR. Gallium-containing anticancer compounds. Future Med Chem. 2012;4(10):1257–72.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gurzau ES, Neagu C, Gurzau AE. Essential metals—case study on iron. Ecotoxicol Environ Safe. 2003;56(1):190–200.CrossRefGoogle Scholar
  53. 53.
    Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 2003;533(1–2):153–71.CrossRefPubMedGoogle Scholar
  54. 54.
    Bernstein LR. 1998: Mechanisms of therapeutic activity for gallium. Fharmacol Rev. 1998;50(4):665–82.Google Scholar
  55. 55.
    Bernstein LR: Therapeutic gallium compounds. metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine. Edited by Gielen and Tiekink. Wiley Ltd. 2005, 14: 259–277Google Scholar
  56. 56.
    Chitambar CR, Wereley JP, Matsuyama S. Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther. 2006;5(11):2834–43.CrossRefPubMedGoogle Scholar
  57. 57.
    Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP. Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther. 2007;322:1228–36.CrossRefPubMedGoogle Scholar
  58. 58.
    Sánchez-Pérez Y, Chirino YI, Osornio-Vargas AR, Morales-Bárcenas R, Gutiérrez-Ruíz C, Vázquez-López I. DNA damage response of A549 cells treated with particulate matter (PM10) of urban air pollutants. Cancer Lett. 2009;278:192–200.CrossRefPubMedGoogle Scholar
  59. 59.
    Mansour A, Daba A, Baddour N, El-Saadani M, Aleem E. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(a)anthracene and decreases cell proliferation: comparison with tamoxifen. J Cancer Res Clin Oncol. 2012;138(9):1579–96.CrossRefPubMedGoogle Scholar
  60. 60.
    Sha S, Jin H, Liu X, Yang J, Ai R, Lu J. Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis. Protein Cell. 2012;3(5):392–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Melnikov, P, Malzac A, Coelho, MB: Gallium and bone pathology. ACTA ORTOP BRAS 2008, 16(1:54–57, 2008)Google Scholar
  62. 62.
    Chitambar CR. Medical applications and toxicities of gallium compounds. Public Health. 2010;7:2337–61.Google Scholar
  63. 63.
    Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69(1):186–97.CrossRefPubMedGoogle Scholar
  64. 64.
    Yang M, Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med. 2008;45:763–72.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Joseph TP, Janine PW, Chitambar CR. Gallium nitrate as a novel agent for the treatment of mantle cell lymphoma: target and mechanisms of action. Proc Am Assoc Cancer Res. 2005;46:1383–4.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of ScienceAin Shams UniversityCairoEgypt
  2. 2.Radiation Biology DepartmentNational Centre for Radiation Research and Technology, Atomic Energy AuthorityCairoEgypt

Personalised recommendations